Floatz logo

ANASTROZOLE

Hypogonadotropic Hypogonadism

Baylor College of MedicineSmall moleculePhase 4 / ApprovedDormant
BBB
73/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
59/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Hypogonadotropic Hypogonadism cohort.

Asset / SponsorPhaseRating
TESTOSTERONE UNDECYLATE
Canisius-Wilhelmina Hospital
Phase 4A
Metformin
University Medical Centre Ljubljana
Phase 4BBB
Liraglutide
University Medical Centre Ljubljana
Phase 4BB
Testim
Odense University Hospital
Phase 4BB
Anakinra
University Hospital, Basel, Switzerland
Phase 3BB

View all 22 →

Same molecule, other indications

ANASTROZOLE is also rated in:

hormone receptor-positive breast cancerActive
BBB
Indicative · Phase 4
74 / 100
View asset →
female breast carcinomaActive
BBB
Indicative · Phase 4
72 / 100
View asset →
invasive breast carcinomaActive
BBB
Indicative · Phase 4
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →